We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 66.68+1.6%Jun 17 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tadsamillionaire who wrote (327)3/12/2007 11:40:06 AM
From: Tadsamillionaire   of 347
Good News for World Kidney Day: GenoMed Can Prevent Most Kidney Failure
GenoMed® (Pink Sheets:GMED), a Next Generation Disease Management company, announced today, World Kidney Day, that it has found drug “recipes” to prevent most kidney failure.

The method was published in a peer-reviewed medical journal in September 2002, but has received little publicity since.

GenoMed’s approach reversed early kidney failure in white, black, and Hispanic patients with diabetes and high blood pressure. Diabetes and high blood pressure cause 90% of kidney failure in the US. Kidney failure affects people of color disproportionately more than whites.

The Centers for Medicaid and Medicare (CMS) currently pay $25 billion annually for kidney dialysis and transplantation. A typical dialysis patient costs $100,000 a year, and lives for less than 3 years on dialysis. When GenoMed’s CEO, Dr. David Moskowitz, briefed CMS about his paper in 2004, the Medical Director and his staff at CMS had no interest. Neither did the National Institutes of Health, nor any non-profit kidney association.

Said Dr. Moskowitz, "In medical school, we were exhorted to find cures. I wouldn't have believed it then if somebody had told me there was no point in finding a cure because news of the cure would be suppressed. Yet that's exactly what's happened for the past four and a half years."

Dr. Moskowitz continued, "Medicine, like any business, thrives on the status quo. Financially small disruptions can be tolerated, like finding cures for polio and TB in the 1950s. Other than the staff of the polio wards and the TB sanitaria, nobody in medicine was hurt financially. But eliminating 90% of a $25 billion a year industry is another thing altogether. Nobody in healthcare wants their budget or their revenues cut."

Added Dr. Moskowitz, “This is the real reason why healthcare costs keep rising. Medicine is fundamentally anti-innovative.”

March 8, 2007 - 9:31 AM EST
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext